RESUMEN
Continuous improvement of protocols for the treatment of various ailments, in particular, osteochondrosis, is one of the important tasks of providing medical care to elderly patients. Supplementation of treatment with Cytoflavin and biofeed-back therapy seems to be a promising solution, however, it is necessary to develop an algorithm to predict it effectiveness in patients taking into account their initial clinical and psychophysiological status. As a result of the treatment, predictors of the effectiveness of the use of Cytoflavin and biofeed-back therapy have been identified and an algorithm for their administration has been developed.
Asunto(s)
Inosina Difosfato , Osteocondrosis , Anciano , Algoritmos , Combinación de Medicamentos , Mononucleótido de Flavina , Humanos , Niacinamida , Succinatos , Resultado del TratamientoAsunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas , Fármacos Gastrointestinales , Animales , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Fármacos Gastrointestinales/efectos adversos , Fármacos Gastrointestinales/farmacocinética , Fármacos Gastrointestinales/uso terapéutico , HumanosRESUMEN
We have experimentally investigated the detoxifying and modifying effects of remaxol in the framework of traditional and high-dose chemotherapy in mice with transplanted tumors. The influence of remaxol in comparison with heptral was studied on the toxic and therapeutic action of cytostatic drugs gemzar, lastet (etoposide), and methotrexate during their traditional and high-dose administration in mice with transplanted P388 lympholeukosis. Remaxol demonstrated a detoxifying action with respect to these cytostatic agents, which decreased in the following series: gemzar lastet methotrexate (according to the results of lethality evaluation). Remaxol significantly increased the therapeutic efficacy of gemzar used in both traditional and high-dose regimes. This was manifested by slowing down tumor growth and increasing animal lifetime during combined administration of the drugs. This may be due to the remaxol potentiation of the antitumor effect of gemzar. In combination with lastet and methotrexate, remaxol does not alter their therapeutic efficacy. The detoxifying action of remaxol with respect to these cytostatics is more pronounced than that of heptral.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Neoplasias Experimentales/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Succinatos/farmacología , Animales , Línea Celular Tumoral , Desoxicitidina/análogos & derivados , Desoxicitidina/farmacología , Etopósido/farmacología , Metotrexato/farmacología , Ratones , GemcitabinaRESUMEN
Preclinical safety of reamberin, a preparation of succinic acid intended for the treatment of patients with shock conditions of different etiology, and remaxol a drug intended for the treatment of patients with liver dysfunction caused by acute intoxication was performed. Both medicines belong to the 5th class of practically non-toxic drugs. Their administration to experimental animals for 30 days did not cause toxic effects on the functional and morphological state of main systems and organs. Both medicines do not affect specific (humoral and cellular) and non-specific immune response and do not cause sensibilization, mutagenic, embryotoxic and teratogenic effects, and also do no alter parameters of reproductive functions of rats.
Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Meglumina/análogos & derivados , Succinatos/efectos adversos , Succinatos/farmacología , Animales , Perros , Evaluación Preclínica de Medicamentos , Femenino , Masculino , Meglumina/efectos adversos , Meglumina/farmacología , Ratas , Choque/tratamiento farmacológicoRESUMEN
Treatment of female SAMP-1 mice with Neuronol (drug containing succinic acid) given with drinking water starting from the age of 2 months during the whole life prolonged the lifespan and markedly reduced mortality of animals aged 1.5-2 years. Neuronol inhibited the development of spontaneous tumors, primarily lymphomas, and significantly prolonged lifespan in mice with tumors. Long-term treatment with Neuronol had no pathological side effects. Our experiments demonstrated geroprotective and anticarcinogenic activity of Neuronol and safety of its long-term use.
Asunto(s)
Envejecimiento/patología , Anticarcinógenos/farmacología , Longevidad/efectos de los fármacos , Neoplasias Experimentales/tratamiento farmacológico , Succinatos/farmacología , Ácido Succínico/farmacología , Animales , Anticarcinógenos/efectos adversos , Evaluación Preclínica de Medicamentos , Femenino , Histiocitoma Fibroso Benigno/tratamiento farmacológico , Histiocitoma Fibroso Benigno/mortalidad , Histiocitoma Fibroso Benigno/patología , Linfoma/tratamiento farmacológico , Linfoma/mortalidad , Linfoma/patología , Ratones , Ratones Endogámicos , Neoplasias Experimentales/mortalidad , Neoplasias Experimentales/patología , Succinatos/efectos adversosRESUMEN
The cycloferon efficacy was investigated in the treatment of experimental herpesvirus kerato-conjunctivitis in rabbits. The model was demonstrated to reflect the main aspects of herpesvirus eye lesions in humans. Cycloferon application similarly to that of known interferon inducer poludan has been shown to enhance processes of inflammation and subsequent regeneration of eye tissues as well as to decrease mortality of animals due to the generalization of infection.